Breaking Business News | Breaking business news AM | Breaking Business News PM

Gilead’s stock has fallen 21% since April 30, underscoring investor questions about remdesivir’s potential

31 Aug 2020

In the four months since Gilead Sciences Inc. first received emergency authorization for its experimental COVID-19 drug remdesivir, its stock has done the opposite of what you would expect — it has dropped 21%.


Read the full article here.
This content was originally published by MarketWatch.com - Top Stories. Original publishers retain all rights. It appears here for a limited time before automated archiving. By MarketWatch.com - Top Stories

Covid-19 – Johns Hopkins University

Download brochure

Introduction brochure

What we do, case studies and profiles of some of our amazing team.

Download